|
|
|
|
| Though the number of CDMOs with mRNA/RNA capabilities is increasing, many of these are better equipped for large-scale, linear mRNA development. Don't miss Advancing RNA Live on January 21st as our panel shares how mRNA and next-gen RNA modality companies need to be evaluating CDMO platforms. Attendance is free thanks to the support of Cytiva. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | In the past few weeks, I’ve shared two articles outlining several RNA executives’ thoughts on advancements from 2024, as well as the challenges facing us in 2025. But why stop there? Below in the first of this two-part article, I share the first two of my five overarching observations from 2024. | |
|
|
|
By S. Ricci, et.al., DeciBio Consulting | As we reflect on the lessons from 2024, it’s time to consider what 2025 may hold for the industry. Special attention is given to oligos, mRNA, cell therapies, and AAV. | |
|
|
|
By Advancing RNA Live | As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today. | |
|
|
|
By Tyler Menichiello, contributing editor | EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time. | |
|
|
|
|
|
|
|
|
| Scalable mRNA Affinity Capture | Application Note | By Jenny England, Ph.D., Thermo Fisher Scientific | The POROS Oligo dT(25) affinity resin offers a solution for the purification of mRNA by providing efficient purification, high binding capacity, and selectivity, while removing impurities. |
|
|
|
| 2025 BioPlan's 22nd Annual Survey--Biopharmaceutical Manufacturing | For over 20 years, we continue to be the leader in providing the biopharma industry's most comprehensive benchmarking analysis. We invite you to participate in our 22nd Annual Survey in Biopharmaceutical Manufacturing! For all completed, qualified responses, we'll send an Amazon egift card, a copy of the summary results (mid-2025), and our 2025 Top Trends in Biomanufacturing White Paper. |
|
|